e-SPACE Heart Failure 2024
Published: 28 October 2024
-
Views:
308
-
Likes:
7
-
Views:
308
-
Likes:
7
-
Up Next -
1h 7m 6s
-
59m 29sPart 1 | Session 4 Plenary session 3 – Obesity and weight management in HF
-
28m 30sPart 1 | Session 5 Special session 2 – Face to face with cardiac amyloidosis
-
1h 10m 15sPart 1 | Session 6 Plenary session 4 – Managing cardiomyopathy in HF
-
1h 4m 48sPart 1 | Session 7 Plenary session 5 – Cardiac rhythm in HF
-
1h 13m 18sPart 1 | Session 8 Plenary session 6 – Devices in HF; time to reassess their place?
-
58m 32sPart 2 | Session 1 Plenary session 7 – Enabling GDMT in HF
-
1h 54sPart 2 | Session 2 Plenary session 8 – Iron deficiency: the totality of evidence
-
59m 41sPart 2 | Session 3 Plenary session 9 – Managing HFpEF in 2024
-
1h 45sPart 2 | Session 4 Plenary session 10 – Valvular heart disease
-
59m 47s
-
1h 57sPart 1 | Session 1 Plenary session 1 – Practical implementation of GDMT in the clinical setting Vijay Chopra, Tarek Bekfani, Gianluigi Savarese, Jasper J Brugts, Justin Ezekowitz
Overview
Translational Medicine Academy (TMA) in partnership with Radcliffe Cardiology were delighted to announce the return of e-SPACE Heart Failure held on the 18-19 October 2024.
e-SPACE Heart Failure 2024 once again provided top-tier free virtual education and optimised geographical reach whilst delivering both global and regional insight. The thoughtfully curated programme explored how leading experts are incorporating heart failure guidelines into clinical practice and offered the latest information on patient profiling in heart failure for tailored medical therapy.
Building on the tremendous success of previous years, this event once again brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
Related sessions to e-SPACE Heart Failure 2024:
- Meet the Experts: SGLT2 Inhibitors in Real Life: Everything the Clinician Needs to Know
- Meet the Experts: GDMT Implementation in HF: How to Tackle Clinical Inertia?
- Meet the Experts: Management of Transthyretin Amyloid Cardiomyopathy (ATTRCM): Optimising Patient Pathways
- Meet the Experts: IV Iron in Clinical Practice: Experts’ Perspectives
- Meet the Experts: Hyperkalemia in HF: Clinical Impact and Long-term Management
- Symposium: SGLT2 Inhibitors in Heart Failure: Updates on Prevention and Treatment
- Meet the Experts: Non-steroidal MRAs: Evolving Role in Heart Failure
Learning Objectives
- Review the burden of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) as one of the leading causes of disability and mortality worldwide
- Understand the latest guideline recommendations and discuss their applicability according to patients phenotypes
- Discuss the implementation in clinical practice of the four foundational therapies and additional drugs and devices to improve patient outcomes
- Develop a comprehensive understanding of best practices for the screening, diagnosis and management of the patient with heart failure and comorbidities
- Translate the findings of recent studies and guidelines into optimal patient management
Target Audience
- Heart Failure Specialists
- General Cardiologists
- General Practitioners (GPs)
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Part 1
Day One
Part 2
Day Two
Faculty Biographies
John J Atherton
Director of Cardiology
Dr John Atherton is Director of Cardiology, Royal Brisbane and Women’s Hospital, Associate Professor, University of Queensland, and Adjunct Professor, Queensland University of Technology.
Dr Atherton was on the board of the Cardiac Society of Australia and New Zealand (CSANZ, 2009–2015) and chairs the CSANZ Professional Ethics Standards Committee. He previously chaired the Asia-Pacific Acute Decompensated Heart Failure Registry Scientific Advisory Committee and the CSANZ Heart Failure Council. Dr Atherton is an appointed member of the Australian Government Medical Services Advisory Committee and provides advice to Government on public funding arrangements through Medicare.
Dr Atherton is Associate Editor, Heart Lung and Circulation, and sits on the editorial board for Cardiac Failure Review. His research interests include screening for pre-symptomatic heart disease and heart failure disease management. His contributions to service enhancement…
Tarek Bekfani
Consultant Cardiologist
Dr Tarek Bekfani is a Consultant Cardiologist at University hospital Magdeburg A.o.R., Magdeburg, DE.
Javed Butler
Professor of Medicine
Dr Javed Butler is President, Baylor Scott and White Research Institute, Senior Vice President for the Baylor Scott and White Health and Professor of Medicine at the University of Mississippi, US. He is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure.
He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.
Prof Butler has authored more than 900 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals and has been cited numerous times in America’s Best Doctors list.
Clara Saldarriaga
Professor of Cardiology
Dr Clara Saldarriaga is an Editorial Board member of Cardiac Failure Review and may be contacted here.
Academic History
Dr Saldarriaga completed her undergraduate studies in Medicine at the Jesus Maria School in Medellin in 1994 and went on to continue her studies at the Medical School at the University of Antioquia in 2002. She then went on to complete her Internal Medicine Residency at the University of Antioquia in 2008.
Career Overview
Dr Saldarriaga is currently a Professor of Cardiology at Cardiovascular Clinic Santa Maria at the University of Antioquia in Medellín. She is a member of…
Faiez Zannad
Professor of Therapeutics and Cardiology, Head of CIC
Prof Faiez Zannad is Professor of Therapeutics & Cardiology and Head of the Division of Heart Failure, Hypertension and Preventive Cardiology for the department of Cardiovascular Disease of the Academic Hospital (CHU) in Nancy and the Director of the Clinical Investigation Centre (Inserm-CHU).
Prof Zannad is currently the Chairman of the ESC Working group on Pharmacology and Drug Therapy as well as a Boardmember of the ESC Heart Failure Association. He is Past-President of the French Society of Hypertension.
Prof Zannad is Co-Editor-in-Chief for Fundamental and Clinical Pharmacology, the official journal of the European Pharmacology Societies Federation (EUPHAR). He chairs and organises annual international meetings on CardioVascular Clinical Trials (CVCT) and on Biomarkers in Heart Failure.